Therapeutic Delivery – Products

MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), announced the signing of a strategic partnership with Prime Medicine, Inc., a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies.

This content pack contains a variety of webinar and technical note resources to support you in building better genetic medicine products. Download this content pack to discover optimized methods for impurity and integrity analysis.

This content pack contains a variety of webinars, technical notes and a compendium of resources to help you overcome a variety of common lentiviral development challenges. Download this content pack to discover innovative solutions for more comprehensive proteome characterization.

Cytiva has launched the NanoAssemblr commercial formulation system, purpose-built for clinical and commercial manufacturing of lipid nanoparticle medicines.

Scribe Therapeutics Inc., a genetic medicines company unlocking the potential of CRISPR to transform human health, announced an expanded collaboration with Sanofi.

Access this exclusive compendium for a selection of Technology Networks’ most popular content in this rapidly developing topic area including infographics, listicles, talk recordings and more.

Developing mRNA-based therapeutics is complex work, requiring highly skilled scientists, high-tech microfluidics platforms and sophisticated analytical equipment, and of course the mRNA itself.

Lipid nanoparticles (LNPs) have emerged as effective delivery vehicles for mRNA vaccines and nucleic acid-based drugs. Hence, the analysis of their composition, stability, and biological interactions is essential in drug development and delivery.

Particle Works is making major contributions to the field of nanomedicine by producing automated microfluidic systems with the potential to improve efficiency in the nanotherapeutic drug development pipeline.

Lipid nanoparticles (LNPs), comprised of ionizable lipids, are used to deliver oligonucleotides to work as therapeutics or to stimulate the immune system, as in the initial mRNA-based COVID vaccines.